Indication
IBM
6 clinical trials
3 products
2 drugs
Clinical trial
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body MyositisStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Product
ABC008Clinical trial
An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 TrialStatus: Terminated, Estimated PCD: 2021-11-15
Product
ArimoclomolClinical trial
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)Status: Completed, Estimated PCD: 2021-01-11
Clinical trial
A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
Cell Therapy for Inclusion Body Myositis (IBM) by Muscle Injection of Autologous Uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a Phase I TrialStatus: Recruiting, Estimated PCD: 2023-10-01
Product
ADSVFClinical trial
A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS)Status: Recruiting, Estimated PCD: 2024-02-01
Drug
sirolimusDrug
Varlilumab